European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

 —Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment— ZUG, Switzerland and BOSTON, Feb. 13, 2024 -- CRISPR Therapeutics , a biopharmaceutical...

Related Keywords

Massachusetts ,United States ,London ,City Of ,United Kingdom ,Switzerland ,San Francisco ,California ,Boston ,France ,Rachel Eides ,Samarth Kulkarni ,Susan Kim ,European Commission ,European Union ,Vertex Pharmaceuticals ,Therapeutics Inc ,Exchange Commission ,Vertex Pharmaceuticals Incorporated ,Globenewswire Inc ,Nasdaq ,Chief Executive Officer ,Sickle Cell Disease ,Transfusion Dependent Beta Thalassemia ,Conditional Marketing Authorizations ,Nobel Prize Winning ,Private Securities Litigation Reform Act ,Markets ,